Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

about

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.

P2860

Q41484469-2F8C0A34-8348-4A38-A6E7-1FA0A7F5B509

P2860

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

Item

http://www.wikidata.org/entity/Q40468733

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase Ib Trial of Cabazitaxel ...... ncer (mCRPC): The CATCH Trial.

@en

type

Item

label

Phase Ib Trial of Cabazitaxel ...... ncer (mCRPC): The CATCH Trial.

@en

prefLabel

Phase Ib Trial of Cabazitaxel ...... ncer (mCRPC): The CATCH Trial.

@en

P1476

Phase Ib Trial of Cabazitaxel ...... ancer (mCRPC): The CATCH Trial

@en

P2093

Andrew J Armstrong

http://www.w3.org/2001/XMLSchema#string

Carolyn Winters

http://www.w3.org/2001/XMLSchema#string

Daniel George

http://www.w3.org/2001/XMLSchema#string

Elia Martinez

http://www.w3.org/2001/XMLSchema#string

Julie Kephart

http://www.w3.org/2001/XMLSchema#string

Kelly Mundy

http://www.w3.org/2001/XMLSchema#string

Michael R Harrison

http://www.w3.org/2001/XMLSchema#string

Michael S Humeniuk

http://www.w3.org/2001/XMLSchema#string

Patrick Healy

http://www.w3.org/2001/XMLSchema#string

Russell Szmulewitz

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

P304

385-395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.23277

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Susan Halabi

P577

2016-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27862097

http://www.w3.org/2001/XMLSchema#string

P932

6309626

http://www.w3.org/2001/XMLSchema#string

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

about

P2860

P2860

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932